Vytlačiť
1.
- Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines / J. Knillová ... [et al.]. Neoplasma : journal of experimental and clinical oncology. - ISSN 0028-2685. - Vol. 51, no. 5 (2004), p. 358-367 : Obr., tab.
- C 720